|
Product Details:
|
| Name: | Mitomycin C | CAS: | 50-07-7 |
|---|---|---|---|
| Reaxys Registry Number: | 3570056 | Storage Temp.: | 0-10°C |
| Assay: | >98.0%(HPLC) | MF: | 334.33 |
| High Light: | CAS 50-07-7 Mitomycin C,Mitomycin C Antibiotic Raw Materials |
||
CAS 50-07-7 Mitomycin C Antibiotic Raw Materials MF C15H18N4O5
| Basic information |
| Product Name: | Mitomycin C |
| CAS: | 50-07-7 |
| MF: | C15H18N4O5 |
| MW: | 334.33 |
| EINECS: | 200-008-6 |
 |
|
| Mitomycin C Chemical Properties |
| Melting point | 360 °C |
| Boiling point | 471.14°C (rough estimate) |
| density | 1.2238 (rough estimate) |
| refractive index | 1.6800 (estimate) |
| storage temp. | 2-8°C |
| solubility | H2O: 4 mL/vial Stock solutions should be filter sterilized and stored at 2-8 °C in the dark., clear to slightly hazy, blue to purple |
| pka | pKa 2.8(H2O,t =25,I=0.1) (Uncertain) |
| PH | pH (0.5 g/l, 25℃ : )5.0～7.0 |
| Water Solubility | soluble |
| Merck | 14,6215 |
| BRN | 7231816 |
| Stability: | Stable. Incompatible with strong acids, strong bases, strong oxidizing agents. |
| CAS DataBase Reference | 50-07-7(CAS DataBase Reference) |
| IARC | 2B (Vol. 10, Sup 7) 1987 |
| EPA Substance Registry System | Mitomycin C (50-07-7) |
| Safety Information |
| Hazard Codes | T,Xn,T+ |
| Risk Statements | 25-40-22-45-26/27/28 |
| Safety Statements | 36/37-45-28A-28-53-22 |
| RIDADR | UN 3462 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | CN0700000 |
| F | 8-10 |
| TSCA | Yes |
| HazardClass | 6.1(a) |
| PackingGroup | II |
| HS Code | 29419090 |
| Hazardous Substances Data | 50-07-7(Hazardous Substances Data) |
| Toxicity | LD50 i.v. in mice: 5 mg/kg (Wakaki); also reported as 9 mg/kg (Kinoshita) |
| Uses | (1) It is a cell division inhibitors, nucleic acid inhibitors and phage inducer; an anti-tumor drugs in clinical use. (2) This drug has a broad anti-tumor spectrum, and effective for gastric cancer, breast cancer. It has a certain effect on lung cancer, liver cancer, malignant lymphoma, Hodgkin's disease, reticular cell sarcoma, uterine cancer, leukemia, intestinal cancer and pancreatic cancer, but with a short remission. Combination with urokinase can improve the efficacy. The goods exert its function quickly, but the number of operators is not high, and it has a high toxicity. The goods and bleomycin as well as its derivatives ——doxorubicin are anti-cancer drugs of antibiotic which can disrupt DNA. It can depolymerize DNA in the cell, inhibit DNA replication in proliferating cell. The LD50 of intravenous injection of mice is 5ml/kg. It acts as an anticancer drugs, commonly used in the treatment of digestive system cancers. |
| Description | Mitomycin C is naturally produced by Streptomyces caespitosus, an Actinobacteria found in soil. Mitomycin C has antibiotic and antitumor activities and has been studied extensively since the 1950s. A unique feature of this drug is strong bioreductive alkylation under hypoxic conditions. Oxygen-poor cells internal to solid tumors provide an environment in which this drug is highly activated. As an antitumor agent, it has shown efficacy in a wide variety of cancers, including gastric cancer, pancreatic cancer, breast cancer, non-small-cell lung cancer, cervical cancer, prostate cancer, and bladder cancer. The sideeffect profile is large, which prohibits its widespread use. Mitomycin C is antibacterial to gram-positive, gram-negative, and acid-fast bacilli. |
| Chemical Properties | Blue-violet crystals or crystalline powder. |
Contact Person: Maggie Ma
Tel: +0086 188 7414 9531
